Form 4: Pediatrix Medical Group EVP, CFO C Marc Richards Reports Acquisition of Restricted Shares

Sentiment:

SEC Form 4


C Marc Richards, EVP and CFO of Pediatrix Medical Group, reports the acquisition of restricted shares as part of an annual equity award.

Summary

  • On June 1, 2024, C Marc Richards, the EVP and Chief Financial Officer of Pediatrix Medical Group, acquired 95,760 shares of common stock at $0.
  • These shares were granted as restricted shares under the company's Amended and Restated 2008 Incentive Compensation Plan as part of an annual equity award.
  • Following the transaction, Richards directly owns 225,347 shares of Pediatrix Medical Group.
  • The restricted shares will vest in three tranches: 25% on June 1, 2025, 25% on June 1, 2026, and 50% on June 1, 2027, subject to the terms of the Plan.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of restricted shares is a standard practice and generally viewed as a positive incentive for executives.

Positives

  • The grant of restricted shares aligns the executive's interests with those of the shareholders.
  • The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This type of equity compensation is common for executives in publicly traded companies to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

  • Granting restricted stock units (RSUs) to executives is a common practice among publicly traded companies, including those in the healthcare sector like UnitedHealth Group (UNH) and HCA Healthcare (HCA).
  • The vesting schedule of 25%-25%-50% over three years is fairly standard, similar to vesting schedules used by companies like Tenet Healthcare (THC).
  • The size of the grant should be compared to the overall compensation package and the company's performance relative to its peers.

Stakeholder Impact

  • Shareholders may view the equity award as a positive incentive for the executive to drive long-term value.
  • Employees may see this as a sign of the company's commitment to its leadership.

Key Dates

DateDescription
06/01/2024Date of transaction: acquisition of restricted shares.
06/01/202525% of restricted shares vest.
06/01/202625% of restricted shares vest.
06/01/202750% of restricted shares vest.
06/04/2024Date of signature.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.